Literature DB >> 34422605

Letter to the editor: the nonnegligible effect of neoadjuvant therapy for patients with borderline resectable pancreatic ductal adenocarcinoma.

Li Wang1, Xin Zhang2, Yanrong Lu1, Bole Tian1.   

Abstract

Entities:  

Year:  2021        PMID： 34422605      PMCID： PMC8340325          DOI： 10.21037/gs-21-379

Source DB:  PubMed          Journal:  Gland Surg        ISSN： 2227-684X


× No keyword cloud information.
  10 in total

1.  Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer.

Authors:  Sohei Satoi; Hideyoshi Toyokawa; Hiroaki Yanagimoto; Tomohisa Yamamoto; Minoru Kamata; Chisato Ohe; Noriko Sakaida; Yoshiko Uemura; Hiroaki Kitade; Noboru Tanigawa; Kentaro Inoue; Yoichi Matsui; A-Hon Kwon
Journal:  J Gastrointest Surg       Date:  2011-12-09       Impact factor: 3.452

2.  Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma.

Authors:  Deyali Chatterjee; Matthew H Katz; Asif Rashid; Jeannelyn S Estrella; Hua Wang; Gauri R Varadhachary; Robert A Wolff; Jeffrey E Lee; Peter W Pisters; James L Abbruzzese; Jason B Fleming; Huamin Wang
Journal:  Histopathology       Date:  2013-09-20       Impact factor: 5.087

3.  Impact of Neoadjuvant Systemic Therapy on Pancreatic Fistula Rates Following Pancreatectomy: a Population-Based Propensity-Matched Analysis.

Authors:  Fadi S Dahdaleh; Samer A Naffouje; Mark H Hanna; George I Salti
Journal:  J Gastrointest Surg       Date:  2020-04-06       Impact factor: 3.452

4.  Preoperative chemoradiation reduces the risk of pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma.

Authors:  Hidenori Takahashi; Hisataka Ogawa; Hiroaki Ohigashi; Kunihito Gotoh; Terumasa Yamada; Masayuki Ohue; Isao Miyashiro; Shingo Noura; Kentaro Kishi; Masaaki Motoori; Tatsushi Shingai; Satoaki Nakamura; Kinji Nishiyama; Masahiko Yano; Osamu Ishikawa
Journal:  Surgery       Date:  2011-05-31       Impact factor: 3.982

5.  Neoadjuvant Therapy Versus Upfront Resection for Pancreatic Cancer: The Actual Spectrum and Clinical Burden of Postoperative Complications.

Authors:  Giovanni Marchegiani; Stefano Andrianello; Chiara Nessi; Marta Sandini; Laura Maggino; Giuseppe Malleo; Salvatore Paiella; Enrico Polati; Claudio Bassi; Roberto Salvia
Journal:  Ann Surg Oncol       Date:  2017-12-06       Impact factor: 5.344

6.  Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-matched analysis.

Authors:  Raphael L C Araujo; Sébastien Gaujoux; Florence Huguet; Mithat Gonen; Michael I D'Angelica; Ronald P DeMatteo; Yuman Fong; T Peter Kingham; William R Jarnagin; Karyn A Goodman; Peter J Allen
Journal:  HPB (Oxford)       Date:  2013-01-10       Impact factor: 3.647

Review 7.  Early postoperative and late metabolic morbidity after pancreatic resections: An old and new challenge for surgeons - A review.

Authors:  Hans G Beger; Benjamin Mayer
Journal:  Am J Surg       Date:  2018-02-16       Impact factor: 2.565

8.  Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.

Authors:  Thomas Hank; Marta Sandini; Cristina R Ferrone; Clifton Rodrigues; Maximilian Weniger; Motaz Qadan; Andrew L Warshaw; Keith D Lillemoe; Carlos Fernández-Del Castillo
Journal:  JAMA Surg       Date:  2019-10-01       Impact factor: 14.766

9.  Prognostic analysis of pancreatic carcinoma with portal system invasion following curative resection.

Authors:  Jing Wang; Shao-Cheng Lyu; Lin Zhou; Han Wang; Fei Pan; Tao Jiang; Ren Lang; Qiang He
Journal:  Gland Surg       Date:  2021-01

10.  Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.

Authors:  Sanne Lof; Maarten Korrel; Jony van Hilst; Adnan Alseidi; Gianpaolo Balzano; Ugo Boggi; Giovanni Butturini; Riccardo Casadei; Safi Dokmak; Bjørn Edwin; Massimo Falconi; Tobias Keck; Giuseppe Malleo; Matteo de Pastena; Ales Tomazic; Hanneke Wilmink; Alessandro Zerbi; Marc G Besselink; Mohammed Abu Hilal
Journal:  Ann Surg Oncol       Date:  2019-12-17       Impact factor: 5.344
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.